These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36458001)

  • 1. Development and external validation of a novel nomogram model for predicting postoperative recurrence-free survival in non-muscle-invasive bladder cancer.
    Ding L; Deng X; Xia W; Wang K; Zhang Y; Zhang Y; Shao X; Wang J
    Front Immunol; 2022; 13():1070043. PubMed ID: 36458001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation.
    Sun JX; An Y; Xu MY; Liu CQ; Xu JZ; Xia QD; Wang SG
    Front Oncol; 2023; 13():1133161. PubMed ID: 37476386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and external validation of a novel nomogram to predict intravesical recurrence after radical nephroureterectomy: a multicenter study.
    Luo Z; Jiao B; Huang T; Zhao H; He W; Bo Y; Ding Z; Zhang G
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11223-11231. PubMed ID: 37355502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.
    Zheng J; Lu S; Huang Y; Chen X; Zhang J; Yao Y; Cai J; Wu J; Kong J; Lin T
    J Transl Med; 2023 Oct; 21(1):685. PubMed ID: 37784106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Systemic Inflammatory Markers as a Significant Prognostic Factor After TURBT in Patients with Non-Muscle-Invasive Bladder Cancer.
    Ding L; Deng X; Wang K; Xia W; Zhang Y; Zhang Y; Shao X; Wang J
    J Inflamm Res; 2023; 16():283-296. PubMed ID: 36713048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomogram for customized recurrence prediction in primary non-muscle-invasive bladder cancer based on routine blood and urine parameters.
    He Y; Pan C; Zhang Y; Lv M; Yang B
    BMC Urol; 2024 Mar; 24(1):67. PubMed ID: 38528549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative systemic immune-inflammation index as a significant prognostic factor after TURBT in patients with non-muscle-invasive bladder cancer: A retrospective study based on propensity score matching analysis.
    Ding L; Wang X; Deng X; Xia W; Wang K; Yu X; Huang Y; Wang J
    Cancer Med; 2023 Mar; 12(6):7019-7028. PubMed ID: 36479836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence.
    Zhao R; Shan J; Nie L; Yang X; Yuan Z; Xu H; Liu Z; Zhou X; Ma W; Shi H
    J Clin Lab Anal; 2021 Aug; 35(8):e23883. PubMed ID: 34184796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
    Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
    Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma.
    Lin WP; Xing KL; Fu JC; Ling YH; Li SH; Yu WS; Zhang YF; Zhong C; Wang JH; Chen ZY; Lu LH; Wei W; Guo RP
    JAMA Netw Open; 2021 Sep; 4(9):e2125055. PubMed ID: 34515782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Nomogram Model to Predict Recurrence of Non-Muscle Invasive Bladder Urothelial Carcinoma After Resection Based on Clinical Parameters and Immunohistochemical Markers.
    Pi J; Xiong Y; Liu C; Liao J; Liu J; Li C; Fu W; Zhao T
    J Invest Surg; 2022 May; 35(5):1186-1194. PubMed ID: 34913802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-Muscle Invasive Bladder Cancer in the Han Chinese Population.
    Wang Z; Gao W; Li J; Wang T; Zhu M; Duan Y
    J Cancer; 2020; 11(7):1668-1678. PubMed ID: 32194779
    [No Abstract]   [Full Text] [Related]  

  • 15. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
    Kohada Y; Hayashi T; Hsi RS; Yukihiro K; Sentani K; Goto K; Inoue S; Ohara S; Teishima J; Kajiwara M; Nishisaka T; Yasui W; Black PC; Matsubara A
    BJU Int; 2021 Apr; 127(4):473-485. PubMed ID: 32805763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
    Xu S; Tan S; Wu T; Gu J; Xu L; Che X
    Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection.
    Mao S; Yu X; Sun J; Yang Y; Shan Y; Sun J; Mugaanyi J; Fan R; Wu S; Lu C
    BMC Cancer; 2022 Mar; 22(1):249. PubMed ID: 35255845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model.
    Yi X; Pi J; Liu C; Xiong Y; Liu J; Fu W; Wang L; Zhao T
    Front Oncol; 2023; 13():1189086. PubMed ID: 37456236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.